Tau-A
A fragment of tau generated by ADAM10, enabling non-invasive monitoring of cognitive decline and neuronal degeneration in neurodegenerative diseases.
Key features and values
- Quantifies ADAM10-generated tau fragments associated with cognitive impairment.
- Provides a non-invasive measure of neuronal degeneration.
- Supports monitoring of disease progression and response to therapies targeting tau pathology.
- Applicable in research on neurodegenerative diseases characterized by tau pathology, such as Alzheimer’s disease.
- Facilitates evaluation of interventions aimed at modulating tau-related neurodegeneration.
- Complements other biomarkers for a comprehensive assessment of tau dynamics.
- Utilized in studies investigating the role of ADAM10-mediated tau cleavage in disease progression.
Description
The TAU-A biomarker assay measures specific fragments of tau protein generated by ADAM10, serving as an indicator of cognitive decline and neuronal degeneration. This non-invasive assay provides insights into tau pathology in neurodegenerative diseases. By quantifying ADAM10-generated tau fragments, the TAU-A assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of tau-related neurodegeneration. It serves as a valuable tool in research settings for assessing the dynamics of tau pathology.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
